1. Home
  2. JSPR vs FEMY Comparison

JSPR vs FEMY Comparison

Compare JSPR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

N/A

Current Price

$1.71

Market Cap

49.5M

Sector

Health Care

ML Signal

N/A

Logo Femasys Inc.

FEMY

Femasys Inc.

N/A

Current Price

$0.77

Market Cap

51.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JSPR
FEMY
Founded
2018
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.5M
51.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
JSPR
FEMY
Price
$1.71
$0.77
Analyst Decision
Buy
Strong Buy
Analyst Count
12
3
Target Price
$25.60
$6.83
AVG Volume (30 Days)
3.8M
1.7M
Earning Date
11-10-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,061,502.00
Revenue This Year
N/A
$64.02
Revenue Next Year
N/A
$147.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.53
52 Week Low
$1.39
$0.31
52 Week High
$23.11
$1.80

Technical Indicators

Market Signals
Indicator
JSPR
FEMY
Relative Strength Index (RSI) 43.99 44.73
Support Level $1.61 $0.79
Resistance Level $1.93 $0.95
Average True Range (ATR) 0.21 0.07
MACD 0.02 -0.02
Stochastic Oscillator 29.61 7.39

Price Performance

Historical Comparison
JSPR
FEMY

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: